Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.

Trial Details

NCT ID
NCT05806580
Phase
PHASE4
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Relma-cel
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients have signed an Informed Consent Form (ICF).
  • Adults diagnosed with relapsed or refractory B-cell lymphoma who have completed initial treatment with Relma-cel.
  • Patients must have undergone at least one disease assessment post-initial Relma-cel treatment, and the investigator decides to administer a second …
  • Before the second infusion, confirm that the prepared dose of relma-cel is sufficient (recommended 80-150 x 10\^6 CAR-T cells), with specific dosag…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →